A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen

Trial Profile

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2011

At a glance

  • Drugs Entecavir; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Apr 2011 Last checked against ClinicalTrials.gov record.
    • 02 Oct 2010 Results will be presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD), according to a Bristol-Myers Squibb media release.
    • 30 Nov 2009 2-year results were published in the Journal of Viral Hepatitis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top